請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92281完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 侯詠德 | zh_TW |
| dc.contributor.advisor | Yung-Te Hou | en |
| dc.contributor.author | 黃婉婷 | zh_TW |
| dc.contributor.author | Wan-Ting Huang | en |
| dc.date.accessioned | 2024-03-21T16:25:05Z | - |
| dc.date.available | 2026-01-29 | - |
| dc.date.copyright | 2024-03-21 | - |
| dc.date.issued | 2024 | - |
| dc.date.submitted | 2024-02-05 | - |
| dc.identifier.citation | Abboud, R., & Vimalanathan, S. (2008). Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema [State of the Art Series. Chronic obstructive pulmonary disease in high-and low-income countries. Edited by G. Marks and M. Chan-Yeung. Number 3 in the series]. The international journal of tuberculosis and lung disease, 12(4), 361-367.
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., & Montes de Oca, M. (2023). Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. American journal of respiratory and critical care medicine, 207(7), 819-837. Akata, K., Yamasaki, K., Leitao Filho, F. S., Yang, C. X., Takiguchi, H., Sahin, B., Whalen, B. A., Yang, C. W. T., Leung, J. M., & Sin, D. D. (2020). Abundance of non-polarized lung macrophages with poor phagocytic function in Chronic Obstructive Pulmonary Disease (COPD). Biomedicines, 8(10), 398. Al Abbady, M. M., Fahmy, A. M., Mahdy, A. A., & Merekab, M. I. (2018). Evaluation of Left Ventricular Systolic Function by Two-Dimentional Speckle Tracking Echocardiography in Patients With Chronic Obstructive Pulmonary Disease (COPD). Egyptian Journal of Hospital Medicine, 72(1). Alifano, M., Cuvelier, A., Delage, A., Roche, N., Lamia, B., Molano, L., Couderc, L., Marquette, C., & Devillier, P. (2010). Treatment of COPD: from pharmacological to instrumental therapies. European Respiratory Review, 19(115), 7-23. Allen, J., & Howell, K. (2014). Microvascular imaging: techniques and opportunities for clinical physiological measurements. Physiological measurement, 35(7), R91. Aloia, E., Cameli, M., D'Ascenzi, F., Sciaccaluga, C., & Mondillo, S. (2016). TAPSE: an old but useful tool in different diseases. International journal of cardiology, 225, 177-183. Alqahtani, J. S. (2022). Prevalence, incidence, morbidity and mortality rates of COPD in Saudi Arabia: Trends in burden of COPD from 1990 to 2019. PLoS One, 17(5), e0268772. Angelis, N., Porpodis, K., Zarogoulidis, P., Spyratos, D., Kioumis, I., Papaiwannou, A., Pitsiou, G., Tsakiridis, K., Mpakas, A., & Arikas, S. (2014). Airway inflammation in chronic obstructive pulmonary disease. Journal of thoracic disease, 6(Suppl 1), S167. Annesley, S. J., & Fisher, P. R. (2019). Mitochondria in health and disease. In (Vol. 8, pp. 680): MDPI. Artyukhov, I. P., Arshukova, I. L., Dobretsova, E. A., Dugina, T. A., Shulmin, A. V., & Demko, I. V. (2015). Epidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, Russia. International journal of chronic obstructive pulmonary disease, 1781-1786. Audrain‐McGovern, J., & Benowitz, N. (2011). Cigarette smoking, nicotine, and body weight. Clinical Pharmacology & Therapeutics, 90(1), 164-168. Balkwill, F. (2006). TNF-α in promotion and progression of cancer. Cancer and Metastasis Reviews, 25, 409-416. Baraldo, S., Turato, G., & Saetta, M. (2012). Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration, 84(2), 89-97. Barnes, P. (2002). Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. European Respiratory Journal, 19(1), 182-191. Barnes, P. J. (2004). Mediators of chronic obstructive pulmonary disease. Pharmacological reviews, 56(4), 515-548. Barnes, P. J. (2010). Inhaled corticosteroids in COPD: a controversy. Respiration, 80(2), 89-95. Barnes, P. J. (2020). Oxidative stress-based therapeutics in COPD. Redox biology, 33, 101544. Barnes, P. J., Shapiro, S. D., & Pauwels, R. (2003). Chronic obstructive pulmonary disease: molecular and cellularmechanisms. European Respiratory Journal, 22(4), 672-688. Bartsch, H., & Nair, J. (2006). Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbeck's Archives of Surgery, 391, 499-510. Bauer, M. E., Jeckel, C. M. M., & Luz, C. (2009). The role of stress factors during aging of the immune system. Annals of the New York Academy of Sciences, 1153(1), 139-152. Beasley, R., Aldington, S., & Robinson, G. (2007). Is it time to change the approach to oxygen therapy in the breathless patient? In (Vol. 62, pp. 840-841): BMJ Publishing Group Ltd. Beddoes, T. (1793). A Letter to Erasmus Darwin, MD on a New Method of Treating Pulmonary Consumption, and Some Other Diseases Hitherto Found Incurable. By Thomas Beddoes, MD (Vol. 1). Bulgin and Rosser; sold by J. Murray; and J. Johnson, London; also by Bulgin …. Belvisi, M. G. (2004). Regulation of inflammatory cell function by corticosteroids. Proceedings of the American Thoracic Society, 1(3), 207-214. Berg, K., & Wright, J. L. (2016). The pathology of chronic obstructive pulmonary disease: progress in the 20th and 21st centuries. Archives of pathology & laboratory medicine, 140(12), 1423-1428. Bhalla, D. K., Hirata, F., Rishi, A. K., & Gairola, C. G. (2009). Cigarette smoke, inflammation, and lung injury: a mechanistic perspective. Journal of Toxicology and Environmental Health, Part B, 12(1), 45-64. Bocalini, D. S., da Silva Luiz, R., Silva, K. A. S., Serra, A. J., Avila, R. A., Leopoldo, A. S., Lima-Leopoldo, A. P., da Cunha, M. R. H., Tucci, P. J. F., & Dos Santos, L. (2020). Short-term cigarette smoking in rats impairs physical capacity and induces cardiac remodeling. BioMed research international, 2020. Bradley, J. M., Nguyen, J. B., Fournett, A. C., & Gardner, J. D. (2012). Cigarette smoke exacerbates ventricular remodeling and dysfunction in the volume overloaded heart. Microscopy and Microanalysis, 18(1), 91-98. Breunig, I. M., Shaya, F. T., & Scharf, S. M. (2012). Delivering cost–effective care for COPD in the USA: recent progress and current challenges. Expert Review of Pharmacoeconomics & Outcomes Research, 12(6), 725-731. Brill, S. E., & Wedzicha, J. A. (2014). Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 1241-1252. Buekers, J., De Boever, P., Vaes, A. W., Aerts, J.-M., Wouters, E. F., Spruit, M. A., & Theunis, J. (2018). Oxygen saturation measurements in telemonitoring of patients with COPD: a systematic review. Expert review of respiratory medicine, 12(2), 113-123. Caliri, A. W., Tommasi, S., & Besaratinia, A. (2021). Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutation Research/Reviews in Mutation Research, 787, 108365. Caramori, G., & Adcock, I. (2003). Pharmacology of airway inflammation in asthma and COPD. Pulmonary pharmacology & therapeutics, 16(5), 247-277. Cavaillès, A., Brinchault-Rabin, G., Dixmier, A., Goupil, F., Gut-Gobert, C., Marchand-Adam, S., Meurice, J.-C., Morel, H., Person-Tacnet, C., & Leroyer, C. (2013). Comorbidities of COPD. European Respiratory Review, 22(130), 454-475. Cazzola, M., Donner, C. F., & Hanania, N. A. (2007). One hundred years of chronic obstructive pulmonary disease (COPD). Respiratory medicine, 101(6), 1049-1065. Chaudhary, B., Dasti, S., Park, Y., Brown, T., Davis, H., & Akhtar, B. (1998). Hour-to-hour variability of oxygen saturation in sleep apnea. Chest, 113(3), 719-722. Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204. Chen, M., Zhang, J., Chen, Y., Qiu, Y., Luo, Z., Zhao, S., Du, L., & Tian, D. (2018). Hydrogen protects lung from hypoxia/re-oxygenation injury by reducing hydroxyl radical production and inhibiting inflammatory responses. Scientific Reports, 8(1), 8004. Ciencewicki, J., & Jaspers, I. (2007). Air pollution and respiratory viral infection. Inhalation toxicology, 19(14), 1135-1146. Cole, A. R., Sperotto, F., DiNardo, J. A., Carlisle, S., Rivkin, M. J., Sleeper, L. A., & Kheir, J. N. (2021). Safety of prolonged inhalation of hydrogen gas in air in healthy adults. Critical care explorations, 3(10). Collins, J.-A., Rudenski, A., Gibson, J., Howard, L., & o’Driscoll, R. (2015). Relating oxygen partial pressure, saturation and content: the haemoglobin–oxygen dissociation curve. Breathe, 11(3), 194-201. Criner, G. J. (2010). COPD and the heart: when less lung means more heart. Chest, 138(1), 6-8. Currie, G. P. (2009). Chronic obstructive pulmonary disease. OUP Oxford. Dalbak, L. G., Straand, J., & Melbye, H. (2015). Should pulse oximetry be included in GPs’ assessment of patients with obstructive lung disease? Scandinavian journal of primary health care, 33(4), 305-310. Dan, Z., Li, H., & Xie, J. (2023). Efficacy of donepezil plus hydrogen–oxygen mixture inhalation for treatment of patients with Alzheimer disease: A retrospective study. Medicine, 102(30), e34382. Davidson, W., & Bai, T. R. (2005). Lung structural changes in chronic obstructive pulmonary diseases. Current Drug Targets-Inflammation & Allergy, 4(6), 643-649. Dole, M., Wilson, F. R., & Fife, W. P. (1975). Hyperbaric hydrogen therapy: a possible treatment for cancer. Science, 190(4210), 152-154. Domej, W., Oettl, K., & Renner, W. (2014). Oxidative stress and free radicals in COPD–implications and relevance for treatment. International journal of chronic obstructive pulmonary disease, 1207-1224. Donohue, J. F., & Ohar, J. A. (2004). Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 1(3), 152-160. Dorey, A., Scheerlinck, P., Nguyen, H., & Albertson, T. (2020). Acute and chronic carbon monoxide toxicity from tobacco smoking. Military Medicine, 185(1-2), e61-e67. Dorman, D. C., Mokashi, V., Wagner, D. J., Olabisi, A. O., Wong, B. A., Moss, O. R., Centeno, J. A., Guandalini, G., Jackson, D. A., & Dennis, W. E. (2012). Biological responses in rats exposed to cigarette smoke and Middle East sand (dust). Inhalation toxicology, 24(2), 109-124. Fahlman, Å. (2014). Oxygen therapy. Zoo animal and wildlife immobilization and anesthesia, 69-81. Fischer, B. M., Pavlisko, E., & Voynow, J. A. (2011). Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation. International journal of chronic obstructive pulmonary disease, 413-421. Füstöss, L., & Toth, G. (1990). The resistance concept and the dynamical characterization of molecular gas flow. Vacuum, 40(1-2), 43-46. Gault, V. A., & McClenaghan, N. H. (2013). Understanding bioanalytical chemistry: principles and applications. John Wiley & Sons. Ghorani, V., Boskabady, M. H., Khazdair, M. R., & Kianmeher, M. (2017). Experimental animal models for COPD: a methodological review. Tobacco induced diseases, 15, 1-13. Godtfredsen, N. S., Lam, T. H., Hansel, T. T., Leon, M., Gray, N., Dresler, C., Burns, D., Prescott, E., & Vestbo, J. (2008). COPD-related morbidity and mortality after smoking cessation: status of the evidence. European Respiratory Journal, 32(4), 844-853. GROUP*, N. O. T. T. (1980). Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Annals of internal medicine, 93(3), 391-398. Guan, W.-J., Wei, C.-H., Chen, A.-L., Sun, X.-C., Guo, G.-Y., Zou, X., Shi, J.-D., Lai, P.-Z., Zheng, Z.-G., & Zhong, N.-S. (2020). Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. Journal of thoracic disease, 12(6), 3448. Guazzi, M., Bandera, F., Pelissero, G., Castelvecchio, S., Menicanti, L., Ghio, S., Temporelli, P., & Arena, R. (2013). Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. American Journal of Physiology-Heart and Circulatory Physiology, 305(9), H1373-H1381. Guide, G. P. (2020). Pocket guide to COPD: Diagonosis, Management, and Prevention: A guide for Healthy Care Professionals. Hanania, N. A., Ambrosino, N., Calverley, P., Cazzola, M., Donner, C. F., & Make, B. (2005). Treatments for COPD. Respiratory medicine, 99, S28-S40. Hansel, N. N., McCormack, M. C., & Kim, V. (2016). The effects of air pollution and temperature on COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 13(3), 372-379. HANSEN, E. F., PHANARETH, K., LAURSEN, L. C., KOK-JENSEN, A., & DIRKSEN, A. (1999). Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 159(4), 1267-1271. Hariprasad, R. (2013). Evaluation of Cardiovascular Changes in Chronic Obstructive Pulmonary Disease and Its correlation with the disease severity Madras Medical College, Chennai]. Harris, J. E. (1996). Cigarette smoke components and disease: cigarette smoke is more than a triad of tar, nicotine, and carbon monoxide. Smoking and tobacco control monograph, 7, 59-75. He, J.-Q., Foreman, M. G., Shumansky, K., Zhang, X., Akhabir, L., Sin, D. D., Man, S. P., DeMeo, D. L., Litonjua, A. A., & Silverman, E. K. (2009). Associations of IL6 polymorphisms with lung function decline and COPD. Thorax, 64(8), 698-704. Ichihara, M., Sobue, S., Ito, M., Ito, M., Hirayama, M., & Ohno, K. (2015). Beneficial biological effects and the underlying mechanisms of molecular hydrogen-comprehensive review of 321 original articles. Medical gas research, 5(1), 1-21. Ikeda, A., Nishimura, K., & Izumi, T. (1998). Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Drugs & aging, 12, 129-137. Jarad, N. (2011). Chronic obstructive pulmonary disease (COPD) and old age? Chronic respiratory disease, 8(2), 143-151. Jones, S. A., & Jenkins, B. J. (2018). Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature reviews immunology, 18(12), 773-789. Jörgensen, K., Müller, M. F., Nel, J., Upton, R. N., Houltz, E., & Ricksten, S.-E. (2007). Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest, 131(4), 1050-1057. Kabir, M. M., Beig, M. I., Baumert, M., Trombini, M., Mastorci, F., Sgoifo, A., Walker, F. R., Day, T. A., & Nalivaiko, E. (2010). Respiratory pattern in awake rats: effects of motor activity and of alerting stimuli. Physiology & behavior, 101(1), 22-31. Kagan, P., Sultan, M., Tachlytski, I., Safran, M., & Ben-Ari, Z. (2017). Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS One, 12(5), e0176173. Kapugi, M., & Cunningham, K. (2019). Corticosteroids. Orthopaedic Nursing, 38(5), 336-339. Kasal, A. (2010). Structure and nomenclature of steroids. Steroid Analysis, 1-25. Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020). A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorganic & medicinal chemistry, 28(5), 115327. Kharitonov, M. A., Tarasov, V. A., Grishaev, S. L., Filippov, A. E., Cherkashin, D. V., Lokshina, T. R., & Varavin, N. A. (2020). Determination of the most informative indicators of right-ventricular dysfunction in patients with chronic obstructive pulmonary disease. Khuder, S. A., & Mutgi, A. B. (2001). Effect of smoking cessation on major histologic types of lung cancer. Chest, 120(5), 1577-1583. Kim, D., Chen, Z., Zhou, L.-F., & Huang, S.-X. (2018). Air pollutants and early origins of respiratory diseases. Chronic diseases and translational medicine, 4(2), 75-94. Kirkham, P. A., & Barnes, P. J. (2013). Oxidative stress in COPD. Chest, 144(1), 266-273. Kohama, K., Yamashita, H., Aoyama-Ishikawa, M., Takahashi, T., Billiar, T. R., Nishimura, T., Kotani, J., & Nakao, A. (2015). Hydrogen inhalation protects against acute lung injury induced by hemorrhagic shock and resuscitation. Surgery, 158(2), 399-407. Laumbach, R. J., & Kipen, H. M. (2012). Respiratory health effects of air pollution: update on biomass smoke and traffic pollution. Journal of allergy and clinical immunology, 129(1), 3-11. LeBaron, T. W., Ohno, K., & Hancock, J. T. (2023). The On/Off History of Hydrogen in Medicine: Will the Interest Persist This Time Around? Oxygen, 3(1), 143-162. Leung, J. M., Tiew, P. Y., Mac Aogáin, M., Budden, K. F., Yong, V. F. L., Thomas, S. S., Pethe, K., Hansbro, P. M., & Chotirmall, S. H. (2017). The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology, 22(4), 634-650. Li, H., Ma, H.-Y., Hua, W.-L., Zhang, Y.-X., Zhang, L., Xing, P.-F., Yang, P.-F., & Liu, J.-M. (2023). Trend of research on the medical use of molecular hydrogen: a bibliometric analysis. Medical gas research, 13(4), 212. Liang, R., Zhang, W., & Song, Y.-M. (2013). Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. Molecular medicine reports, 7(5), 1470-1476. Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., & Bonaduce, D. (2018). Oxidative stress, aging, and diseases. Clinical interventions in aging, 757-772. Liu, B., Xie, Y., Chen, J., Xue, J., Zhang, X., Zhao, M., Jia, X., Wang, Y., & Qin, S. (2021). Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice. Journal of Inflammation Research, 14, 5541. Liu, S.-L., Liu, K., Sun, Q., Liu, W.-W., Tao, H.-Y., & Sun, X.-J. (2011). Hydrogen therapy may be a novel and effective treatment for COPD. Frontiers in Pharmacology, 2, 19. Liu, T., Wang, F.-P., Wang, G., & Mao, H. (2017). Role of neutrophil extracellular traps in asthma and chronic obstructive pulmonary disease. Chinese medical journal, 130(06), 730-736. Liu, X., Ma, C., Wang, X., Wang, W., Li, Z., Wang, X., Wang, P., Sun, W., & Xue, B. (2017). Hydrogen coadministration slows the development of COPD-like lung disease in a cigarette smoke-induced rat model. International journal of chronic obstructive pulmonary disease, 1309-1324. Lomas, D. A. (2016). Does protease–antiprotease imbalance explain chronic obstructive pulmonary disease? Annals of the American Thoracic Society, 13(Supplement 2), S130-S137. López‐Campos, J. L., Tan, W., & Soriano, J. B. (2016). Global burden of COPD. Respirology, 21(1), 14-23. Lu, W., Li, D., Hu, J., Mei, H., Shu, J., Long, Z., Yuan, L., Li, D., Guan, R., & Li, Y. (2018). Hydrogen gas inhalation protects against cigarette smoke-induced COPD development in mice. Journal of thoracic disease, 10(6), 3232. Luch, A. (2005). Nature and nurture–lessons from chemical carcinogenesis. Nature Reviews Cancer, 5(2), 113-125. Lundblad, L. K., Thompson-Figueroa, J., Leclair, T., Sullivan, M. J., Poynter, M. E., Irvin, C. G., & Bates, J. H. (2005). Tumor necrosis factor–α overexpression in lung disease: a single cause behind a complex phenotype. American journal of respiratory and critical care medicine, 171(12), 1363-1370. Luo, W., Yu, H., Gou, J., Li, X., Sun, Y., Li, J., & Liu, L. (2020). Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). MacNee, W., & Donaldson, K. (2000). Exacerbations of COPD: environmental mechanisms. Chest, 117(5), 390S-397S. MacNee, W., Rabinovich, R. A., & Choudhury, G. (2014). Ageing and the border between health and disease. European Respiratory Journal, 44(5), 1332-1352. Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C., & Boffetta, P. (2016). Risk factors for lung cancer worldwide. European Respiratory Journal, 48(3), 889-902. Manisalidis, I., Stavropoulou, E., Stavropoulos, A., & Bezirtzoglou, E. (2020). Environmental and health impacts of air pollution: a review. Frontiers in public health, 8, 14. Mannino, D. M. (2002). COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest, 121(5), 121S-126S. Mannino, D. M., Buist, A. S., & Vollmer, W. M. (2006). Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. Matsumoto, K., Aizawa, H., Inoue, H., Koto, H., Takata, S., Shigyo, M., Nakano, H., & Hara, N. (1998). Eosinophilic airway inflammation induced by repeated exposure to cigarette smoke. European Respiratory Journal, 12(2), 387-394. Matta, S., Rajpal, S., Chopra, K., & Arora, V. (2021). Covid-19 vaccines and new mutant strains impacting the pandemic. The Indian Journal of Tuberculosis, 68(2), 171. Mautz, W. J., & Bufalino, C. (1989). Breathing pattern and metabolic rate responses of rats exposed to ozone. Respiration physiology, 76(1), 69-77. McEvoy, C. E., & Niewoehner, D. E. (2000). Corticosteroids in chronic obstructive pulmonary disease: clinical benefits and risks. Clinics in chest medicine, 21(4), 739-752. McGuinness, A. J. A., & Sapey, E. (2017). Oxidative stress in COPD: sources, markers, and potential mechanisms. Journal of clinical medicine, 6(2), 21. Mess, A. (1999). The evolutionary differentiation of the rostral nasal skeleton within Glires. A review with new data on lagomorph ontogeny. Zoosystematics and Evolution, 75(2), 217-228. Moerloose, K. B., Pauwels, R. A., & Joos, G. F. (2005). Short-term cigarette smoke exposure enhances allergic airway inflammation in mice. American journal of respiratory and critical care medicine, 172(2), 168-172. Moldoveanu, B., Otmishi, P., Jani, P., Walker, J., Sarmiento, X., Guardiola, J., Saad, M., & Yu, J. (2008). Inflammatory mechanisms in the lung. Journal of Inflammation Research, 1-11. Mortola, J. P. (2004). Breathing around the clock: an overview of the circadian pattern of respiration. European journal of applied physiology, 91, 119-129. Mosser, D. M., Hamidzadeh, K., & Goncalves, R. (2021). Macrophages and the maintenance of homeostasis. Cellular & molecular immunology, 18(3), 579-587. Mroz, R., Noparlik, J., Chyczewska, E., Braszko, J., & Holownia, A. (2007). Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. Journal of Physiology and Pharmacology, 58(5), 453-460. Nova, Z., Skovierova, H., & Calkovska, A. (2019). Alveolar-capillary membrane-related pulmonary cells as a target in endotoxin-induced acute lung injury. International Journal of Molecular Sciences, 20(4), 831. O'byrne, P., & Postma, D. (1999). The many faces of airway inflammation: asthma and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 159(supplement_2), S1-S63. O'donnell, R., Breen, D., Wilson, S., & Djukanovic, R. (2006). Inflammatory cells in the airways in COPD. Thorax, 61(5), 448. Ofoedu, C. E., You, L., Osuji, C. M., Iwouno, J. O., Kabuo, N. O., Ojukwu, M., Agunwah, I. M., Chacha, J. S., Muobike, O. P., & Agunbiade, A. O. (2021). Hydrogen peroxide effects on natural-sourced polysacchrides: free radical formation/production, degradation process, and reaction mechanism—a critical synopsis. Foods, 10(4), 699. Ohta, S. (2011). Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. Current pharmaceutical design, 17(22), 2241-2252. Ohta, S. (2012). Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. Biochimica et Biophysica Acta (BBA)-General Subjects, 1820(5), 586-594. Ohta, S. (2014). Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacology & therapeutics, 144(1), 1-11. Organization, W. H. (2020). The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death Øvrevik, J., Refsnes, M., Låg, M., Holme, J. A., & Schwarze, P. E. (2015). Activation of proinflammatory responses in cells of the airway mucosa by particulate matter: oxidant-and non-oxidant-mediated triggering mechanisms. Biomolecules, 5(3), 1399-1440. Pappas, L. E., & Nagy, T. R. (2019). The translation of age-related body composition findings from rodents to humans. European journal of clinical nutrition, 73(2), 172-178. Pappas, R. S. (2011). Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization. Metallomics, 3(11), 1181-1198. Puchner, A., & Blüml, S. (2014). IL-6 blockade in chronic inflammatory diseases. Wiener Medizinische Wochenschrift (1946), 165(1-2), 14-22. Rao, X., Zhong, J., Brook, R. D., & Rajagopalan, S. (2018). Effect of particulate matter air pollution on cardiovascular oxidative stress pathways. Antioxidants & redox signaling, 28(9), 797-818. Reczyńska, K., Tharkar, P., Kim, S. Y., Wang, Y., Pamuła, E., Chan, H.-K., & Chrzanowski, W. (2018). Animal models of smoke inhalation injury and related acute and chronic lung diseases. Advanced drug delivery reviews, 123, 107-134. Rehman, A. U., Hassali, M. A. A., Muhammad, S. A., Harun, S. N., Shah, S., & Abbas, S. (2020). The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. The European Journal of Health Economics, 21, 181-194. Rigas, F., & Sklavounos, S. (2008). Hydrogen safety. In Hydrogen Fuel (pp. 547-580). CRC Press. Ringbaek, T. J., & Lange, P. (2014). Trends in long-term oxygen therapy for COPD in Denmark from 2001 to 2010. Respiratory medicine, 108(3), 511-516. Roca, M., Verduri, A., Corbetta, L., Clini, E., Fabbri, L. M., & Beghé, B. (2013). Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. European journal of clinical investigation, 43(5), 510-521. Roche, N., Gaillat, J., Garre, M., Meunier, J.-P., Lemaire, N., & Bendjenana, H. (2010). Acute respiratory illness as a trigger for detecting chronic bronchitis in adults at risk of COPD: a primary care survey. Primary Care Respiratory Journal, 19(4), 371-377. Rosa, R. C., Pereira, S. C., Cardoso, F. A. G., Caetano, A. G., Santiago, H. A. R. d., & Volpon, J. B. (2017). Second hand tobacco smoke adversely affects the bone of immature rats. Clinics, 72, 785-789. Rosas, P. C., Neves, L. A., Senese, P. B., & Gralinski, M. R. (2023). Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension. JoVE (Journal of Visualized Experiments)(191), e63775. Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. International journal of biological sciences, 8(9), 1237. Rose-John, S. (2018). Interleukin-6 family cytokines. Cold Spring Harbor perspectives in biology, 10(2), a028415. Rose‐John, S. (2017). The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clinical Pharmacology & Therapeutics, 102(4), 591-598. Sethi, J. M., & Rochester, C. L. (2000). Smoking and chronic obstructive pulmonary disease. Clinics in chest medicine, 21(1), 67-86. Sethi, S. (2004). Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proceedings of the American Thoracic Society, 1(2), 109-114. Siafakas, N., Vermeire, P., Pride, N. a., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., & Postma, D. (1995). Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal, 8(8), 1398-1420. https://erj.ersjournals.com/content/erj/8/8/1398.full.pdf Skwarski, K. M., Gorecka, D., Sliwinski, P., Hogg, J. C., & MacNee, W. (1993). The effects of cigarette smoking on pulmonary hemodynamics. Chest, 103(4), 1166-1172. Su, J.-c., Zhang, Y., Cheng, C., Zhu, Y.-n., Ye, Y.-m., Sun, Y.-k., Xiang, S.-y., Wang, Y., Liu, Z.-b., & Zhang, X.-f. (2021). Hydrogen regulates the M1/M2 polarization of alveolar macrophages in a rat model of chronic obstructive pulmonary disease. Experimental Lung Research, 47(7), 301-310. Sun, J., Bao, J., Shi, Y., Zhang, B., Yuan, L., Li, J., Zhang, L., Sun, M., Zhang, L., & Sun, W. (2017). Effect of simvastatin on MMPs and TIMPs in cigarette smoke-induced rat COPD model. International journal of chronic obstructive pulmonary disease, 717-724. Sun, X., Li, Q., Gong, Y., Ren, L., Wan, H., & Deng, W. (2012). Low-dose theophylline restores corticosteroid responsiveness in rats with smoke-induced airway inflammation. Canadian journal of physiology and pharmacology, 90(7), 895-902. Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology, 6(10), a016295. Tarpy, S. P., & Celli, B. R. (1995). Long-term oxygen therapy. New England Journal of Medicine, 333(11), 710-714. Tazerji, S. S., Shahabinejad, F., Tokasi, M., Rad, M. A., Khan, M. S., Safdar, M., Filipiak, K. J., Szarpak, L., Dzieciatkowski, T., & Jurgiel, J. (2022). Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene reports, 26, 101505. Teramoto, S. (2007). 1. COPD pathogenesis from the viewpoint of risk factors. Internal medicine, 46(2), 77-80. Tetley, T. D. (2005). Inflammatory cells and chronic obstructive pulmonary disease. Current Drug Targets-Inflammation & Allergy, 4(6), 607-618. Tian, Y., Zhang, Y., Wang, Y., Chen, Y., Fan, W., Zhou, J., Qiao, J., & Wei, Y. (2021). Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis. Frontiers in physiology, 12, 789507. Tji-Joong Gan, C., Lankhaar, J.-W., Marcus, J. T., Westerhof, N., Marques, K. M., Bronzwaer, J. G., Boonstra, A., Postmus, P. E., & Vonk-Noordegraaf, A. (2006). Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology, 290(4), H1528-H1533. Tuder, R. M., Yoshida, T., Arap, W., Pasqualini, R., & Petrache, I. (2006). State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proceedings of the American Thoracic Society, 3(6), 503-510. Turnheim, K. (2004). Drug therapy in the elderly. Experimental gerontology, 39(11-12), 1731-1738. Usmani, O. S. (2019). Choosing the right inhaler for your asthma or COPD patient. Therapeutics and clinical risk management, 461-472. Viegi, G., Simoni, M., Scognamiglio, A., Baldacci, S., Pistelli, F., Carrozzi, L., & Annesi-Maesano, I. (2004). Indoor air pollution and airway disease [State of the Art]. The international journal of tuberculosis and lung disease, 8(12), 1401-1415. Vizza, C. D., Lynch, J. P., Ochoa, L. L., Richardson, G., & Trulock, E. P. (1998). Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest, 113(3), 576-583. Vlahovic, G., Russell, M. L., Mercer, R. R., & Crapo, J. D. (1999). Cellular and connective tissue changes in alveolar septal walls in emphysema. American journal of respiratory and critical care medicine, 160(6), 2086-2092. Wager-Srdar, S. A., Levine, A., Morley, J., Hoidal, J., & Niewoehner, D. (1984). Effects of cigarette smoke and nicotine on feeding and energy. Physiology & behavior, 32(3), 389-395. Wagner, P. D. (2015). The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases. European Respiratory Journal, 45(1), 227-243. Wallimann, P., Marti, T., Fürer, A., & Diederich, F. (1997). Steroids in molecular recognition. Chemical reviews, 97(5), 1567-1608. Wang, G., Mohammadtursun, N., Sun, J., Lv, Y., Jin, H., Lin, J., Kong, L., Zhao, Z., Zhang, H., & Dong, J. (2018). Establishment and evaluation of a rat model of sidestream cigarette smoke-induced chronic obstructive pulmonary disease. Frontiers in physiology, 9, 58. Wang, S.-T., Bao, C., He, Y., Tian, X., Yang, Y., Zhang, T., & Xu, K.-F. (2020). Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients. QJM: An International Journal of Medicine, 113(12), 870-875. Wang, Y., Jiang, X., Zhang, L., Wang, L., Li, Z., & Sun, W. (2014). Simvastatin mitigates functional and structural impairment of lung and right ventricle in a rat model of cigarette smoke-induced COPD. International Journal of Clinical and Experimental Pathology, 7(12), 8553. Webster, J. G. (1997). Design of pulse oximeters. Crc Press. Weitzenblum, E., Sautegeau, A., Ehrhart, M., Mammosser, M., Hirth, C., & Roegel, E. (1984). Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. American Review of Respiratory Disease, 130(6), 993-998. White, C. W., & Repine, J. E. (1985). Pulmonary antioxidant defense mechanisms. Experimental Lung Research, 8(2-3), 81-96. Woods, J. A., Wheeler, J. S., Finch, C. K., & Pinner, N. A. (2014). Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 421-430. Wu, S., Ni, Y., Li, H., Pan, L., Yang, D., Baccarelli, A. A., Deng, F., Chen, Y., Shima, M., & Guo, X. (2016). Short-term exposure to high ambient air pollution increases airway inflammation and respiratory symptoms in chronic obstructive pulmonary disease patients in Beijing, China. Environment international, 94, 76-82. Yan, W., Chen, T., Long, P., Zhang, Z., Liu, Q., Wang, X., An, J., & Zhang, Z. (2018). Effects of post-treatment hydrogen gas inhalation on uveitis induced by endotoxin in rats. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 24, 3840. Yang, D., Xu, D., Wang, T., Yuan, Z., Liu, L., Shen, Y., & Wen, F. (2021). Mitoquinone ameliorates cigarette smoke-induced airway inflammation and mucus hypersecretion in mice. International Immunopharmacology, 90, 107149. Yang, M., Dong, Y., He, Q., Zhu, P., Zhuang, Q., Shen, J., Zhang, X., & Zhao, M. (2020). Hydrogen: a novel option in human disease treatment. Oxidative Medicine and Cellular Longevity, 2020. Yohannes, A. M., & Hardy, C. C. (2003). Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs & aging, 20, 209-228. Zhao, C.-z., Fang, X.-c., Wang, D., & Wang, X.-d. (2010). Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease. Respiratory medicine, 104(10), 1391-1395. Zhao, H., Jaffer, T., Eguchi, S., Wang, Z., Linkermann, A., & Ma, D. (2015). Role of necroptosis in the pathogenesis of solid organ injury. Cell death & disease, 6(11), e1975-e1975. Zheng, H., Liu, Y., Huang, T., Fang, Z., Li, G., & He, S. (2009). Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Toxicology Letters, 189(3), 225-234. Zheng, Z.-G., Sun, W.-Z., Hu, J.-Y., Jie, Z.-J., Xu, J.-F., Cao, J., Song, Y.-L., Wang, C.-H., Wang, J., & Zhao, H. (2021). Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial. Respiratory research, 22(1), 149. Zhou, Z.-Q., Zhong, C.-H., Su, Z.-Q., Li, X.-Y., Chen, Y., Chen, X.-B., Tang, C.-L., Zhou, L.-Q., & Li, S.-Y. (2018). Breathing hydrogen-oxygen mixture decreases inspiratory effort in patients with tracheal stenosis. Respiration, 97(1), 42-51. 日本厚生勞動省. (2016). https://www.mhlw.go.jp/topics/bukyoku/isei/sensiniryo/kikan03.html 日本慶應大學. (2016). 水素ガス吸入療法. https://www.hosp.keio.ac.jp/about/yakuwari/senshin/senshin16.html 台灣氫氧應用研究推廣學會. (2014). 氫分子醫學保健及疾病治療論文彙集. https://h2bestdrug.blogspot.com/2014/12/blog-post_16.html 克利夫蘭診所的護理. https://my.clevelandclinic.org/health/diseases/8709-chronic-obstructive-pulmonary-disease-copd 周星輝, & 謝文斌. (2001). 吸入型類固醇於慢性阻塞性肺疾的治療. 當代醫學(329), 176-180. https://doi.org/10.29941/mt.200103.0002 衛生福利部. (2021a). https://www.mohw.gov.tw/dl-83733-80fb9ab8-ea2d-4e3e-ba06-f70f28aca036.html 衛生福利部. (2021b). 110年國人死因統計結果. https://www.mohw.gov.tw/cp-16-70314-1.html 衛生福利部國民健康署. (2021). https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1718&pid=9913 | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92281 | - |
| dc.description.abstract | 本研究目的是探討氫氧產生器在慢性阻塞性肺病 (Chronic obstructive pulmonary disease; COPD) 動物模型中的應用機制，並進一步探究其對 COPD 治療的潛力。COPD 是一種常見的呼吸系統疾病，目前最常見的治療方式不外乎是氣體治療 (氧氣) 與藥物治療 (類固醇) 等，但這些都只能暫緩此病症，因此研究者希冀能找尋一種新型的治療方法來減緩或是降低 COPD 的症狀。氫氧治療在既往文獻中已經被證明對身體多個器官如肝臟、腎臟、肺臟等，具備抗發炎的治療效果。因此，本研究擬使用能穩定提供富含氧氣和氫氣的氫氧產生器 (Hydrogen-Oxygen generator) 來治療 COPD。此種治療方式具有以下特點：(1) 氫氣具有抗氧化、抗發炎的效果；(2) 氫氧產生器為非藥物型的治療，可有效的降低對藥物的依賴性，也降低藥物潛在的副作用或是相互作用 (如常見的類固醇治療)、亦可以降低藥物治療的醫療成本；(3) 氫氧產生器更可提供額外的氫氣與氧氣，可以有效減緩呼吸困難。而在實驗過程中，我們首先建立了大鼠的香菸煙霧模型以模擬 COPD 患者，接著我們進一步評估 COPD 大鼠在接受氫氧產生器治療後的各種生理現象和生化指標，以驗證其對 COPD 治療的效果。
研究結果可知：在大鼠的香菸煙霧模型中，發現：(1) 大鼠暴露在香菸煙霧中的第二周開始，大鼠的體重之間就出現顯著的差異性。控制組 (未吸菸組) 的體重在第一個月、第二個月、第三個月相較於吸菸組重 25%, 24%, 26%；(2) 在支氣管肺泡灌洗液 (Bronchoalveolar lavage fluids; BALF) 中，大鼠在經過香菸煙霧處理三個月後，其總白血球數量、嗜中性球、淋巴球、單核球則分別增加了 1.71, 1.26, 4.11, 2.1 倍；(3) 大鼠在經過香菸煙霧處理三個月後，其三尖瓣環收縮期偏移 (Tricuspid annular systolic excursion; TAPSE) 數值在第二個月、第三個月相較於第一個月分別下降了 67.1%、42.8%。 另一方面，受到香菸煙霧損傷後的大鼠，再進一步給予氫氧產生器的治療後顯示：(1) 在總白血球數值中，給予氫氧產生器的治療之數值僅有吸菸損傷後自然恢復的 0.83 倍，但是給予類固醇的治療反而增加 2 倍；而控制組 (未吸菸組) 再額外給予類固醇後的總白血球數值相較於單純的控制組反而增加了 1.88倍；(2) 在嗜中性球數值中，給予氫氧產生器的治療之數值僅有吸菸損傷後自然恢復的 0.74 倍，但是給予類固醇的治療反而增加 3.48 倍； (3) 在平均線性截距 (Mean linear intercept; MLI) 數值中，給予氫氧產生器的治療之數值下降至僅有吸菸損傷後自然恢復的 0.53 倍；(4) 在肺泡密度的平均值 (Mean value of alveolar density; MAN) 數值中，給予氫氧產生器的治療相較於吸菸損傷後自然恢復的情形增加 1.2 倍； (5) 在三尖瓣環收縮期偏移 (TAPSE) 數值中，給予氫氧產生器的治療之數值上升至僅有吸菸損傷後自然恢復的 1.08 倍。 根據以上結果，我們可以成功地建立一套大鼠的香菸煙霧模型、且肺部受損的大鼠在給予氫氧產生器治療後的效果明顯優於類固醇。除此之外，氫氧產生器可通過水電解的方式，產出我們需要的氫氣與氧氣 (流速、濃度、比例都可依情況調控)，這種方式不但簡便也更為環保。相信這樣的技術能給予 COPD 患者一個新的臨床治療策略、也期待其對於推進相關學科領域的研究發展具有重要的意義。 | zh_TW |
| dc.description.abstract | The objective of this study is to investigate the application mechanism of a hydrogen-oxygen generator in a chronic obstructive pulmonary disease (COPD) animal model and explore its potential for COPD treatment. COPD is a common respiratory disease, and the current standard treatments involve gas therapy (oxygen) and medication (steroids), which only provide temporary relief. Therefore, researchers aim to find a novel treatment method to alleviate or reduce COPD symptoms. Hydrogen therapy has been proven in previous literature to have anti-inflammatory effects on various organs, including the liver, kidneys, and lungs. In this study, a hydrogen-oxygen generator, capable of stably providing oxygen and hydrogen, will be used for COPD treatment. This treatment approach has the following characteristics: (1) Hydrogen has antioxidant and anti-inflammatory effects. (2) The hydrogen-oxygen generator provides a non-pharmacological treatment, effectively reducing dependence on medication, lowering potential side effects or interactions associated with drugs (such as common steroid treatments), and decreasing medical costs. (3) The generator can supply additional hydrogen and oxygen, effectively alleviating respiratory difficulties. In the experimental process, we first established a cigarette smoke model in rats to simulate COPD patients. Subsequently, we evaluated various physiological and biochemical indicators in COPD rats after receiving treatment with the hydrogen-oxygen generator to validate its effectiveness in COPD treatment.
The research findings indicate that in the rat model exposed to cigarette smoke: (1) From the second week of exposure to cigarette smoke, significant differences in body weight among rats were observed. The control group (non-smoking group) showed a weight gain of 25%, 24%, and 26% compared to the smoking group in the first, second, and third months, respectively. (2) In the Bronchoalveolar Lavage Fluid (BALF), after three months of exposure to cigarette smoke, rats exhibited a respective increase of 1.71-fold, 1.26-fold, 4.11-fold, and 2.1-fold in total white blood cell count, neutrophils, lymphocytes, and monocytes. (3) Tricuspid annular systolic excursion (TAPSE) values decreased by 67.1% and 42.8% in the second and third months, respectively, after three months of cigarette smoke treatment compared to the first month. On the other hand, in rats damaged by cigarette smoke and subsequently treated with a hydrogen-oxygen generator: (1) The treatment with the hydrogen-oxygen generator resulted in a total white blood cell count only 0.83-fold of the natural recovery after smoking damage. In contrast, steroid treatment increased it by 2-fold. Additional steroid treatment in the control group (non-smoking group) increased the total white blood cell count by 1.88-fold compared to the control group without treatment. (2) The neutrophil count with hydrogen-oxygen generator treatment was only 0.74-fold of the natural recovery after smoking damage, while steroid treatment increased it by 3.48-fold. (3) The Mean Linear Intercept (MLI) with hydrogen-oxygen generator treatment was reduced it by 0.53-fold of the natural recovery after smoking damage. (4) The Mean Value of Alveolar Density (MAN) with hydrogen-oxygen generator treatment increased by 1.2-fold compared to the natural recovery after smoking damage. (5) In the tricuspid annular systolic excursion (TAPSE) values, treatment with a hydroxyl generator increased the value to 1.08 times that of spontaneous recovery after smoking injury only. Based on the above results, we have successfully established a rat model exposed to cigarette smoke, and the therapeutic effects of a hydrogen-oxygen generator on rats with lung damage are significantly superior to steroids. In addition, the hydrogen-oxygen generator can produce the required hydrogen and oxygen through water electrolysis, with the flow rate, concentration, and ratio adjustable as needed. This method is not only convenient but also more environmentally friendly. We believe that such technology can provide a new clinical treatment strategy for COPD patients and anticipate its significant impact on advancing research development in related disciplines. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-03-21T16:25:05Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2024-03-21T16:25:05Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 誌謝 i
摘要 ii Abstract iv 目次 vii 圖次 x 第ㄧ章 前言 1 1.1 研究背景 1 1.2 研究目的 4 1.3 國內外研究現狀 6 國內 6 國外 6 1.4 實驗架構 7 第二章 文獻探討 9 2.1 COPD 發展過程 9 2.1.1 COPD 發病機制 9 2.2 COPD 的危險因子 11 2.2.1 香菸 11 2.2.2 空氣汙染 12 2.2.3 年紀 13 2.3 COPD 的氧化作用與發炎因子 14 2.3.1 TNF-α 14 2.3.2 IL-6 16 2.4 COPD 的治療方式 20 2.4.1 藥物治療 20 2.4.1.1 類固醇 20 2.4.1.2 β2 受體激動劑 22 2.4.2 氣體治療 24 2.4.2.1 氧氣治療 24 2.4.2.2 氫氣治療 25 2.4.2.3氫氧氣治療 27 2.5 具體目標 28 第三章 研究方法 30 3.1 實驗藥品與材料 30 3.1.1 實驗藥品 30 3.1.2 實驗耗材 30 3.2 實驗儀器與軟體 31 3.2.1 實驗儀器 31 3.2.2 實驗軟體 31 3.3 實驗動物 32 3.4 檢測分析方法 33 3.4.1 全血球計數分析 33 3.4.2 支氣管肺泡灌洗 35 3.4.3 組織染色 Hematoxylin and eosin stain (H&E) 36 3.4.4 組織染色 Picro-Sirius Red Stain 37 3.4.5 組織染色 Periodic Acid-Schiff stain (PAS) 38 3.4.6 組織染色 Immunohistochemistry (IHC) 38 3.4.7 Peripheral capillary oxygen saturation (SpO2) 檢測 39 3.5 統計分析 41 3.6 設備的製作與系統的建立 42 3.7 動物模型的建立 44 第四章 結果與討論 46 4.1 香菸煙霧模型的機構設計結果 46 4.2 體重分析 49 4.3 BALF 分析 52 4.4 組織分析 60 4.5 超音波分析 63 4.6 SpO2 分析 69 第五章 結論與未來展望 72 5.1 結論 72 5.2 未來展望 74 參考資料 76 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 純水電解氫氧機(pure water electrolysis hydrogen-oxygen machine) | zh_TW |
| dc.subject | 氫氧產生器(Hydrogen-oxygen generator) | zh_TW |
| dc.subject | 人體臨床試驗(human clinical trial) | zh_TW |
| dc.subject | COPD動物模型(animal model) | zh_TW |
| dc.subject | 非危急性支氣管炎(non-critical bronchitis) | zh_TW |
| dc.subject | Non-critical bronchitis | en |
| dc.subject | Chronic obstructive pulmonary disease-animal model | en |
| dc.subject | Human clinical trial | en |
| dc.subject | Pure water electrolysis hydrogen-oxygen machine | en |
| dc.subject | Hydrogen-oxygen generator | en |
| dc.title | 以氫氧產生器應用於 COPD 疾病模型之治療 | zh_TW |
| dc.title | Application of a Hydrogen-Oxygen Generator for the Treatment of COPD Disease Models | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 112-1 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 鄭宗記;陽光耀 | zh_TW |
| dc.contributor.oralexamcommittee | ZONG-JI ZHENG;GUANG-YAO YANG | en |
| dc.subject.keyword | 氫氧產生器(Hydrogen-oxygen generator),純水電解氫氧機(pure water electrolysis hydrogen-oxygen machine),非危急性支氣管炎(non-critical bronchitis),COPD動物模型(animal model),人體臨床試驗(human clinical trial), | zh_TW |
| dc.subject.keyword | Hydrogen-oxygen generator,Pure water electrolysis hydrogen-oxygen machine,Non-critical bronchitis,Chronic obstructive pulmonary disease-animal model,Human clinical trial, | en |
| dc.relation.page | 90 | - |
| dc.identifier.doi | 10.6342/NTU202400349 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2024-02-07 | - |
| dc.contributor.author-college | 生物資源暨農學院 | - |
| dc.contributor.author-dept | 生物機電工程學系 | - |
| 顯示於系所單位： | 生物機電工程學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-112-1.pdf 未授權公開取用 | 3.68 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。